MORRISVILLE, N.C.--(BUSINESS WIRE)--Cirrus Pharmaceuticals, a Kemwell company, which is a 100% services oriented company providing pharmaceutical contract development and manufacturing services, announced that it will be investing in a flexible cGMP suite in its facility in RTP, North Carolina.
Ninad Deshpanday, President of R&D at Kemwell said, “With this investment, we are bringing our customers a new service from our US facility. We will offer our clients cGMP manufacturing services for many dosage forms including inhalation, liquids, topicals and oral solids. This service will enable our clients to enter clinic faster. We have completed the design phase and expect the suite to be ready to service customers by April 2015.”
Today, Kemwell’s R&D division employs over 175 scientists worldwide and provides services ranging from formulation development, analytical development and validation to clinical trial manufacturing. The team has experience working on early stage development programs for NCEs, ANDAs, 505(b)(2) and product life cycle management projects for various customers across the world, including virtual, small and big pharma. With the addition of the cGMP suite, Cirrus will be able to extend its offerings in the US from contract development to manufacturing.
About Cirrus, a Kemwell company:
Cirrus, a contract product development organization based in RTP, NC, USA, was acquired by Kemwell in 2013. Kemwell is a 100% CDMO, servicing pharmaceutical and biopharmaceutical organizations worldwide for over 30 years. With integrated facilities in India, Sweden and the US, Kemwell delivers a full portfolio of services for sterile and non-sterile products from pre-formulation to commercial supply worldwide. Our 1200+ global workforce offers proven expertise in inhaled, nasal, oral, parenteral and topical dosage forms.
Read more about on www.cirruspharm.com and www.kemwellpharma.com
